Melbourne, Australia; 3 March 2021:
The UPcare Group announced today that its research arm Apex Biotech Research has officially signed a cooperative agreement with Dr. Dan Zhang. The agreement is to create a joint initiative to carry out a multinational clinical trials of UPcare Groups "UPplus A" formulation.
In future, UPcare Group will have two divisions, the complementery medicine division run by UPcare Group and a registered medicine division run jointly with YuanMing Capital. Both divisions will have different priorities and target markets, however they will both be committed to providing safe, natural and effective solutions to reduce respiratory infections and fight against the pandemic.
Pre-clinical testing carried out by the Peter Doherty Institute has shown that when combined the Upcare Groups compounds "UPplus-A, UPplus-U and UPplus-P have the ability to inhibit Sars-CoV-2 virus in Vero cells.
UPcare Groups Chairman Professor Zhicheng Xiao explained that the UPplus compounds generate antiviral activity, reduces symptoms of respiratory tract infections and it also inhibits SARS-Cov-2 virus proliferation.
It has been reported pre-clinical testing that UPplus compounds reduces SARS-Cov-2 infection rates by decreasing the receptor ACE2 expression. It boosts immune systems, also reducing the likelihood of a secondary bacterial infection. This broad-spectrum antiviral activity provides a basis for future pandemic solutions.
The UPcare Group is committed to turning their current products which are both Australian and USA government authority approved therapeutic products into registered medicines that can be used by hospitals, governments and WHO in the global fight against Coronavirus.
In order for their products to become registered medicines the UPcare Group will first need to carry out human trials. Dr. Zhang, one of the worlds most respected clinical CRO experts has joined the team at the UPcare Group to help fast track the preparation of multi-site clinical trials with the aim of getting approval from WHO so their products can be featured on WHO's emergency use list.
UPcare Group welcome more investors and distributors to join us, for more information, please contact: enquiries@upcare.tech
About UPcare Group
UPCare Group Pty Ltd global biopharmaceutical company and a world leader in the development of pharmaceutical and medical products based on natural botanic combinations called UPplus® with programs for COVID-19. UPcare has developed UPplus KBD Spray™ (an antiviral oral spray for COVID-19) and UPplus A Capsules™, (an antiviral capsule) for COVID-19, which are complementary to vaccines and other preventative measures such as distancing and PPE. Both UPplus® products are approved by both Australia and USA government authorities.
As a leading company in the botanic based drug delivery, UPcare’s proprietary drug delivery platform Apex Biotech Research, which has been collaborating with the prestigious Monash Univeristy is being used to screening compounds, improve pharmaceuticals, to reduce toxicities and enhance their performance.
About UPplus KBD Spray™
UPPlus KBD Spray ™is an essential complementary medicine with two powerful compounds UP-U and UP-P and designed to assist everyone against respiratory infections. As a broad spectrum spray, it an easy to use antiviral oral spray, which can be stored at room temperature and does not require refrigeration. UPPLUS KBD Spray™ helps:
Enhance/promote general health and wellbeing
Enhance/improve/promote immune defence/immunity
Helps reduce occurrence of symptoms of upper respiratory tract infections
Relieve dry throat
Relieve itchy throat
UPplus KBD Spray™ contains UP-U and UP-P （Reynoutria japonica extract and Eriobotrya japonica extract）where UP-U has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses in safe dosage, including >80% of coronavirus SARS-CoV-2 (the virus that causes COVID-19). UP-U has been shown to be virucidal, inactivating >82.2% of SARS-CoV-2 within 48 hours.
Scientific research also shows that UP-U and UP-P to have both passed toxcity study, and already in clinical trial stage. The upper respiratory site including throat is the primary site where SARS-CoV-2 (COVID-19) becomes established for around 4 days, before spreading to the lungs. The virus is irreversibly blocked and inhibited from infecting mucosal cells, thereby providing a physical barrier to respiratory viruses in the throat.
UPplus KBD Spray formulation is patented by Apex Biotech under UPcare Group. UPplus KBD Spray™ could provide additional support, in addition to conventional PPE and vaccine-based prevention strategies, for frontline doctors, nurses and other essential workers and in crowded and high-risk environments, such as public transport and aged care. It also compliement Vaccine to boost more immunity and reduce upper respiratory tract infections.
UPplus KBD Spray™ is registered for sale in Australia and USA （Both Approved）, and is also available for sale online now via www.upcare.tech
About UPplus A Capsules™
UPplus A Capsules™ are powerful complementary medicines combining three natural compunds of UPplus-A, UPplus-U and UPplus-P to assist people against respiratory infections. UPPLUS A Capsules™ help:
Enhance/improve/promote immune defence/immunity
Decrease/reduce/relieve mild bronchial irritation
Relieve symptoms of mild upper respiratory tract infections
Decrease/reduce/relieve symptoms of common cold
Decrease/reduce/relieve cough Maintain/support lung health
Relieve symptoms of sore throat/pharyngitis
UPplus A Capsules™ contains UP-A, UP-U and UP-P where the UP-A has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.7% of coronavirus SARS-CoV-2 (the virus that causes COVID-19) in vitro. Three compounds combination also has been shown similar level of antivirus capability, inactivating >99.7% of SARS-CoV-2 within 48 hours within safe dosage.
UPplus A Capsules™ could provide stronger additional line of defence in addition to conventional PPE and vaccines for frontline workers and people in crisis environment such as public transport and aged care. UPplus formulation is patented by Apex Biotech under UPcare Group and a specific PCT patent application has been filed for its use in capsules.
UPplus A Capsule™ is registered for sale in Australia (Approved) and USA (Pending）, and is available for sale online, www.upcare.tech
About Dr. Dan ZHANG
Dr. Zhang was a member of grant review committee for National Drug Development Fund of China, and was also a consultant for the China National Medical and Pharmaceutical Administration. He is a member of ICH E19 Expert Working Group. He was the Chair Person for the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association.
Dr. Zhang was also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. Dr. Zhang was the board of directors for the Sino-American Pharmaceutical Association and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix-a biotechnology association originated from the Bay Area of San Francisco of USA. Dr. Zhang is an international member of Russian Academy of Engineering.
Comments